## ANTINEOPLASTIC AGENTS. SYNTHESIS OF SOME 1-SUBSTITUTED 5-FLUOROURACIL DERIVATIVES

## Masao TADA

The Research Institute for Tuberculosis, Leprosy and Cancer,
Tohoku University, Hirosemachi, Sendai 980

Reactions of 5-fluorouracil with various acyl chlorides, alkane-sulfonyl chlorides, and arenesulfonyl chlorides in dioxane or dimethyl-formamide gave the 1-substituted derivatives. Some of these products showed markedly antitumor activity.

Since the introduction of 5-fluorouracil  $(I)^{1}$  as antineoplastic agent, many 5-fluorouracil derivatives have been prepared in an effort to increase and to modify activity. Recently, 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) (II) was employed as clinical drugs for certain solid tumors by oral administration, which shows minimal gastro-intestinal toxicity. However, II is much inferior to I in antitumor activity and is necessary to be improved in the aforesaid activity. The introduction of chemically simple groups into the 1-position of I might be useful to obtain the desired compounds. This paper describes the preparations of 1-acyl-, 1-alkane-sulfonyl-, and 1-arenesulfonyl-5-fluorouracils.

When I was allowed to react with acyl, alkanesulfonyl, and are nesulfonyl chlorides in dioxane or dimethylformamide in the presence of tertiary amine or anhydrous potassium carbonate, the corresponding 1-substituted 5-fluorouracil was produced. The structures of these products were established by microanalyses and by the spectral data.

The typical reaction procedure is described for the reaction of I with p-chlorobenzoyl chloride. To a suspension of I (2.6 g, 20 mmol) in dioxane (40 ml) and triethylamine (10 ml), p-chlorobenzoyl chloride (8.4 g, 40 mmol) was added. The mixture was stirred at 80°C for 6 hr, cooled to room temperature, and then filtered off. The filtrate was evaporated to dryness under reduced pressure and the residue was extracted with absolute ethanol. The extract was concentrated by evaporation. The resulting crystals which separated were recrystallized from ethanol to give 1-(p-chlorobenzoyl)-5-fluorouracil (1.18 g, 35%). In a similar manner, various 1-substituted compounds were obtained from I as shown in Table 1.

The above products have been submitted for animal testing. The results indicate that benzoyl and are nesulfonyl derivatives are more active and less toxic than II in Leukemia L-1210 system. 5)

The reactions of I with other acyl chlorides and arenesulfonyl chlorides are currently under investigation.

Table 1. 1-Substituted 5-Fluorouracil Derivatives

HN F  O N  CO R			HN F O N SO 2 R		
R	Mp <sup>a)</sup> (°C)	Yield (%)	R	Mp <sup>a</sup> ) (°C)	Yield (%)
CH <sub>3</sub>	126-127 <sup>b)</sup>	61	CH <sub>3</sub>	223-224	45
CH <sub>3</sub> CH <sub>2</sub>	124-125	52	CH <sub>3</sub> CH <sub>2</sub>	214-215	23
<sup>C</sup> 6 <sup>H</sup> 5	170-172	43	d-10-Camphoryl	153-154	59
о-СH <sub>3</sub> С <sub>6</sub> H <sub>4</sub>	180-181	36	<sup>C</sup> 6 <sup>H</sup> 5	256-257	55
p-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	198-199	49	o-СH <sub>3</sub> С <sub>6</sub> H <sub>4</sub>	204-205	37
p-ClC <sub>6</sub> H <sub>4</sub>	185-186	35	p-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	241-242	62
2,4-(C1) <sub>2</sub> C <sub>6</sub> H <sub>3</sub>	175-177	69	2,4,6-(CH <sub>3</sub> ) <sub>3</sub> C <sub>6</sub> H <sub>2</sub>	232-233	21
p-NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub>	182-183	53	p-CH <sub>3</sub> CH <sub>2</sub> C <sub>6</sub> H <sub>4</sub>	215-216	43
o-CH3 <sup>OC</sup> 6 <sup>H</sup> 4	183-184	56	p-BrC <sub>6</sub> H <sub>4</sub>	247-248	58
p-CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>	200-201	49	p-ClC <sub>6</sub> H <sub>4</sub>	237-238	45
2-Furyl	165–166	71	p-IC <sub>6</sub> H <sub>4</sub>	253-254	50
			p-CH <sub>3</sub> CONHC <sub>6</sub> H <sub>4</sub>	240-241 <sup>c)</sup>	36
			o-NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub>	229-231	59
			l-Naphthyl	218-221	62
			2-Thienyl	222-223	70
			8-Quinolyl	272-273 <sup>c)</sup>	62

a) All melting points are uncorrected. b) Lit., 4) mp 128-129°C. c) Decomp. point.

The author is grateful to Professor Yusaku Ikegami of Tohoku University for his encouragement and to Mitsui Pharmaceuticals, Inc., for supplying 5-fluorouracil.

## References

- 1) R. Duschinsky, E. Pleven, and C. Heidelberger, J. Amer. Chem. Soc., 79, 4559 (1957).
- 2) J. A. Montgomery, Cancer Res., <u>19</u>, 447 (1959); C. Heidelberger, Ann. Rev. Pharmacol., <u>7</u>, 101 (1967); Cancer Res., <u>30</u>, 1549 (1970).
- 3) S. A. Giller, R. A. Zhnk, M. J. Lidak, and A. A. Zidermane, British Pat. 1168391 (1969); Japan Pat. 10510 (1974).
- 4) M. Hoffer, Japan Pat. 8284 (1962).
- 5) A. Hoshi, M. Iigo, N. Nakamura, and K. Kuretani, Gann, <u>65</u>, 463 (1974).

(Received December 2, 1974)